Pharmacy Residency Program Directors

Tricia Parker, Joy Vongspanich Dray and Teresa Kwong
Tricia Parker, Joy Vongspanich Dray and Teresa Kwong, PGY1 Residency Program Directors

Joy Vongspanich Dray
Email: jdray@ucdavis.edu

Current Title(s):

  • Senior Clinical Pharmacist, Solid Organ Transplant
  • PGY1 Residency Program Director
  • Assistant Clinical Professor, UCSF School of Pharmacy

At UC Davis Medical Center since: 2010

Program Director since: 2017

Education:

  • PharmD, University of California, San Francisco 2010·        
  • PGY1 Ambulatory Care/HIV Residency, UC Davis Medical Center, 2011

Professional Biography

Dr. Joy Vongspanich Dray is a Senior Ambulatory Care Clinical Pharmacist at UC Davis Health. She completed her PGY1 Ambulatory Care/HIV residency here at UC Davis in 2011 and went on to work as a clinical pharmacist practicing in solid organ transplant. There she helped to develop the clinical services of the solid organ transplant specialty pharmacy. In 2013 she returned to her first passion, serving the HIV population at the Center for AIDS Research and Education Services (CARES). Since then, Dr Dray has continued to practice in both areas of clinical specialties expanding the role of clinical pharmacists in both specialty clinics. Dr Dray has a special interest in volunteering abroad, having served in India, Thailand, Kenya and Uganda. She hopes to continue to pursue her love of international service and spread awareness to future residents by co-precepting an elective rotation in rural Uganda.

Dr Dray is board certified in Ambulatory Care and credentialed by the American Academy of HIV medicine as a practicing HIV Pharmacist. In addition, she holds a volunteer faculty position with the UCSF School of Pharmacy and has earned various pharmacy awards, most notably Preceptor of the Year, 2016-2017.

Selected Publications

Yu M, Dray J, Nguyen J. Analysis of Clinical Outcomes Associated with Generic to Generic Interchange of Tacrolimus in Renal Transplantation. Presented at ACCP 2019.

Asmuth DM, Chen AY, Utay NS, Torok N, Poole PL, Vongspanich J, Haight KR, Sumasunderam AD, Byambaa E, Li X-D, Cohen ST, Berglund L, Holodniy M, Michalak TI. Impact of Occult HCV Infection (OCI) on Systemic Immune Activation after DAA Therapy. In Abstracts for the 25rd Conference on Retroviruses and Opportunistic Infections. Boston MA, USA, March 4-7, 2018. Abstract 636.

Mitchell Y, Volpendesta J, Wilson M, Dray J. Evaluation of efficiency and patient perception of transplant medication education after pharmacist created education video. Presented at Healthcare Con and American Transplant Congress 2018.

Hluhanich R, Vongspanich J, Poole P, Wilson M. Management of Hypertensive HIV-positive Patients in a Patient-Centered Medical Home. Presented at IDSA and ACCP 2014.

Created “Transplant medication education” videos. Available on UCD Health CCTV and websites

Teresa Kwong
Email: terkwong@ucdavis.edu

Current Title(s):

  • Senior Pharmacist, UC Davis Health Clinics
  • PGY1 Pharmacy Residency Director – Ambulatory Care
  • Assistant Professor, UC San Francisco School of Pharmacy
  • Assistant Processor, University of the Pacific School of Pharmacy

At UC Davis Health since: 2005

Program Director since: 2008

Education:

  • PharmD, University of the Pacific, 2005
  • PGY-1 Pharmacy Practice Residency, UC Davis Medical Center, 2005 - 2006

Professional Biography

Dr. Teresa Kwong is an ambulatory care pharmacist at UC Davis Health Clinics. She is board certified in ambulatory care and pharmacotherapy. Dr. Kwong began her pharmacy career at UC Davis Health in 2005. She completed a PGY1 pharmacy practice residency in 2006. Upon completion of her residency she accepted a position with the UC Davis Health ambulatory care clinics. She has held roles in the anticoagulation, refill, medication therapy management, hypertension/hyperlipidemia, and controlled substance clinics. She has been a PGY-1 pharmacy residency program director since 2008.  

Selected Publications

Batth, S, Branch, J, Giannini, J, Kwong, T, and Wilson, M. Impact of a Clinical Pharmacist’s Interventions on Patient’s Knowledge of Direct Oral Anticoagulants (DOAC). Presented at the Anticoagulation Forum National Conference 2017.

Nguyen, J, Dang, J, and Kwong, T. Evaluation of Safety and Effectiveness of 12 Week Monitoring of Patients Stable on Warfarin at UC Davis Anticoagulation Clinic. Presented at the American College of Clinical Pharmacy Annual Meeting 2013.

Mendoza, P, Kwong, T, Duong, L, and Burton, J. Evaluation of Causes of Supratherapeutic INR at the UC Davis Health Anticoagulation Clinic. Presented at the American Society of Health System Pharmacists Midyear 2013.

Kwong, T, Shepard, T, Burton, J, Bandy, J, Branch, J, and Giannini, J. Evaluating Time in Therapeutic Range of Warfarin Patients Self Testing With Point of Care Devices. Presented at California Society of Health-System Pharmacists Seminar 2011.

Louie, D, and Kwong, T. Identifying Methods to Improve the Referral Process in Patients Discharged from a University Hospital to an Outpatient Anticoagulation Clinic. Presented at University Health System Consortium meeting at the American Society of Health-System Pharmacists Midyear 2010.

Kwong, T, Sexton, L, Burton, J, Bandy, J, Branch, J, and Giannini, J. Development and Production of a Patient-Specific Warfarin Education Video for a University Teaching Hospital and Outpatient Anticoagulation Clinic. Presented at American Society of Health-System Pharmacists Midyear 2009.

Nguyen, K, Kwong, T, Giannini, J, and Mowers, R. Retrospective Analysis of TZD Utilization Based on FDA Safety Warnings. Presented at University Health System Consortium meeting at the American Society of Health-System Pharmacists Midyear 2008.

Kwong T. (2006). New Treatment Options for Deep Vein Thrombosis and Pulmonary Embolism. UC Davis Medical Center Drug Perspectives. 1, 3-4.

Kwong, T, Dager, W, and King, J. Evaluation of the Use of Low Molecular Weight Heparins for Venous Thromboembolism Prophylaxis in Trauma Patients. Presented at University Health System Consortium meeting at the American Society of Health-System Pharmacists Midyear 2005.

Tricia Parker
Email: mailto:plparker@ucdavis.edu

Current Title(s):

  • Assistant Chief, UC Davis Medical Center Inpatient Pharmacy Services
  • Health Sciences Associate Clinical Professor,
    UC San Francisco School of Pharmacy
  • Health Sciences Associate Clinical Professor,
    UC Davis School of Medicine,
    Division of Pulmonary & Critical Care Medicine

At UC Davis Medical Center since: 1999

Program Director since: 2009

Education:

  • PharmD, Creighton University School of Pharmacy and Health Professions, 1999
  • Pharmacy Practice Residency, UC Davis Medical Center, 2000
  • Masters of Science in Health Services Administration, Quality and Performance Improvement, University of Wyoming, 2019
  • Institute for Healthcare Improvement Fellowship 2021

Professional Biography

Dr. Patricia (Tricia) Parker is the Assistant Chief of Inpatient Pharmacy Services at UC Davis Medical Center. Dr. Parker joined the UC Davis Medical Center team in 1999 as one of three Acute Care PGY1 residents, and accepted a career position upon graduation as a Critical Care Staff Pharmacist. In 2003, she was promoted to a Clinical Services Supervisor where she practiced in a split clinical (Critical Care & Nutrition Support) and administrative role for the next five years. Serving as Assistant Chief/Clinical Coordinator since 2008, Dr. Parker is currently responsible for the oversight of planning, implementing and management of clinical pharmacy practice throughout the inpatient setting, assuring efficient and effective clinical services.

Dr. Parker's commitment to hospital pharmacy practice began in 1988 where she worked as a hospital technician for seven years before entering pharmacy school at Creighton University in Omaha, Nebraska in 1995.

In addition to her Assistant Chief/Clinical Coordinator role, she has since obtained faculty positions at both UC San Francisco School of Pharmacy and UC Davis School of Medicine as a Health Sciences Associate and Assistant Professor, respectively. In 2009, Dr. Parker was appointed as the PGY-1 Acute Care Residency Director for UC Davis Medical Center.

Selected Publications

Delich PC, Siepler JK, Parker, P. Liver Diseases. In: The ASPEN Nutrition Support Core Curriculum. Gottschich MM, Editor. American Society for Parenteral and Enteral Nutrition. Silver Spring, MD pp. 540-557.

Stebbins MR, Cutler TW, and Parker PL. Assessment of Therapy and Medication Therapy Management. In Applied Therapeutics: The Clinical Use of Drugs. 9th edition. Koda-Kimble MA, Young LY, Kradjan WA, Guglielmo BJ, Alldredge BK, Corelli RL, Williams BR eds. Lippincott, Williams & Wilkins: Baltimore, MD, 2008.

Clemens E, Cutler T, Canaria J, Pandya K, and Parker P. Prescriber Compliance with a New Computerized Insulin Guideline for Noncritically Ill Adults. The Annals of Pharmacotherapy 2011; February, Volume 45.

Stebbins MR, Cutler TW, and Parker PL. Assessment of Therapy and Medication Therapy Management. In Applied Therapeutics: The Clinical Use of Drugs. 10th edition. Koda-Kimble MA, Young LY, Kradjan WA, Guglielmo BJ, Alldredge BK, Corelli RL, Williams BR eds. Lippincott, Williams & Wilkins: Baltimore, MD, 2012.

Cutler TW, Parker PL. Medication Errors in the Intensive Care Unit. ICU Management, vol. 9, no. 2, pp. 12-15.

Pandya PA, Firestone R, Parker P, Duby JJ. Enhancing Quality and Safety in Insulin Therapy: A multi-disciplinary approach to create and validate continuous infusion insulin protocols. American Journal of Medical Quality. 2014; 29: 23S

Murthy MS, Duby JJ, Parker PL, Durbin-Johnson BP, Roach DM, Louie EL. Blood glucose response to rescue dextrose in hypoglycemic, critically ill patients receiving an insulin infusion. Ann Pharmacother. 2015 Aug;49(8):892-6.

Schomer KJ, Firestone RL, Parker PL, et. al. Hypoactive Delirium in the Critical Care Setting. Delirium: Prevention, Symptoms and Treatment. Bourgeois JA, Editor. Nova Science Publishers, Inc., New York. 2017.

Firestone RL, Parker PL, Pandya KA, Wilson MD, Duby JJ. Moderate-Intensity Insulin Therapy Is Associated With Reduced Length of Stay in Critically Ill Patients With Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State. Crit Care Med. 2019 Mar 7.

Christopher B. Adams
Email: chradams@ucdavis.edu

Current Title(s):

  • Senior Clinical Pharmacist, Emergency Medicine
  • Assistant Clinical Professor, UC San Francisco School of Pharmacy
  • Assistant Clinical Professor, UC Davis School of Medicine

    At UC Davis Medical Center since: 2014

    Program Director since: 2018

    Education:

    • Bachelor of Science, Loyola University New Orleans, 2008
    • Doctor of Pharmacy, Oregon State University, 2012
    • PGY1 Pharmacy Residency, Oregon Health & Science University, 2013
    • PGY2 Emergency Medicine, University of Rochester Medical Center, 2014

    Professional Biography

    Dr. Christopher Adams is the Senior Pharmacist in Emergency Medicine and the Emergency Medicine Pharmacy Residency Program Director for the University of California Davis Medical Center. Dr. Adams graduated from Oregon State University and Oregon Health and Science University (OHSU) in 2012 and then a completed a PGY1 Pharmacy Residency at OHSU in 2013. He then sought further education and experience in emergency medicine and completed the PGY2 Emergency Medicine Pharmacy Residency in 2014 at the University of Rochester Medical Center. Following residency he accepted a position with UC Davis Health, focusing on Emergency Medicine. Dr. Adams serves as an Assistant Clinical Professor for the UC San Francisco School of Pharmacy and precepts pharmacy students and residents in Emergency Medicine. Dr. Adams also serves as an Assistant Clinical Professor for the UC Davis School of Medicine where he teaches a Wilderness Medicine elective to medical, physician assistant and nurse practitioner students. In addition, he is a Ski Patroller in the Lake Tahoe region and is certified in Outdoor Emergency Care (OEC), Emergency Neurological Life Support (ENLS), Pediatric Advanced Life Support (PALS) and is an instructor for Advanced Cardiovascular Life Support (ACLS). Finally, Dr. Adams is a Board Certified Critical Care Pharmacist (BCCCP).

    Dr. Adams strives to play an instrumental role in the development of Emergency Medicine Pharmacy Services at UC Davis Health and beyond. He serves as a peer reviewer for the Annals of Emergency Medicine and Academic Emergency Medicine. He volunteers his time as part of the American Society of Health-System Pharmacists (ASHP) Section Advisory Group on Emergency Care and as part of the Acute Medical Team at the California International Marathon.

    Research is a driving force within UC Davis Health Emergency Department. Dr. Adams works closely with Emergency Medicine Faculty to ensure research and care initiative are successful. His research interests include Emergency Medicine Pharmacy educational opportunities locally and nationally, tranexamic acid and substance abuse disorders.

    Dr. Adams has been involved with the UC Davis Health PGY2 Emergency Medicine Pharmacy Residency Program since its inception in 2014. In 2018, Dr. Adams was appointed to Residency Program Director and hopes to expand the residency to diversify clinical services and maximize the cultivation of outstanding pharmacists with a prospective career in Emergency Medicine Pharmacy.

    Selected Publications

    Catlin JR, Adams CB, Louie DJ, Wilson MD, Louie EN. Aggressive versus conservative initial diuretic dosing in the emergency department for acute decompensated heart failure. Ann Pharmacother. 2018;52(1):26-31.

    Adams CB, Vollman KE, Leventhal EL, Acquisto NM. Emergent pediatric anticoagulation reversal using a 4-factor prothrombin complex concentrate. Am J Emerg Med. 2016;34(6):1182.e1-2.

    Adams CB, Acquisto NM, Rotoli JM, Lostracco T, Shamaskin AR, Pasternack JS. Superior mesenteric artery thrombosis after abrupt discontinuation of rivaroxaban. Am J Emerg Med. 2016;34(4):764.e5-7.

    Vollman KE, Adams CB, Shah, MN, Acquisto NM. Survey of emergency medicine pharmacy education opportunities for students and residents. Hosp Pharm. 2015;50(8)690-99. Adams CB, Schult R, Acquisto NM, Wiegand TJ. 2014 Annual Meeting of the North American Congress of Clinical Toxicology: Bupropion exposures seizures and severe toxicity. Clin Toxicol (Phila). 2014;52(7)769-70.

    Buxell S, Adams CB. Pharmacy Pulse. Department of Pharmacy, Oregon Health & Science University. Oct 2012; Apr 2013

    Seaton S, Lyons K, Flannery A, Adams CB, Birk R, Lettsome R, Mottice B, Pon T, Siv M. Student Commentary: Purpose and Impact of Introductory Pharmacy Practice Experiences. Pharmacotherapy. June 2011 [accepted]

    Seaton S, Lyons K, Flannery A, Adams CB, Birk R, Lettsome R, Mottice B, Pon T, Siv M. National Student Newsletter: StuNews. American College of Clinical Pharmacy website. www.accp.com. Jan 2011; Apr 2011; Aug 2011; Dec 2011; Mar 2012; June 2012; Aug 2012

    Julianna Burton
    Email: julburton@ucdavis.edu

    Current Title(s):

    • Associate Chief of Pharmacy, Population Health
    • Pharmacy Lead, Population Health
    • Associate Clinical Professor of Pharmacy, UCSF School of Pharmacy
    • Assistant Professor, University of the Pacific

    At UC Davis Medical Center since: 2004

    Program Director since: 2021

    Education:

    • Doctor of Pharmacy, University of the Pacific, 1999
    • PGY1 Pharmacy Practice Resident, St. Joseph’s Medical Center, 2000
    • Masters of Business Administration, 2018

    Professional Biography

    Dr. Burton earned a Doctorate of Pharmacy from University of the Pacific in 1999 and completed a residency in pharmacy practice at St. Joseph’s Hospital in Stockton in 2000. Prior to transitioning into management, Dr. Burton practiced as a clinical pharmacist in anticoagulation and cardiology ambulatory care. During the last 16 years as a manager, Dr. Burton has initiated pharmacist run clinical programs in hypertension, hyperlipidemia, congestive heart failure, and diabetes. Dr. Burton has helped develop the UC Davis Anticoagulation Clinic, and she played an active role in the hospital’s initial expansion of Specialty Services in Hepatitis C, Rheumatology, Neurology, Gastroenterology, and Dermatology. In addition, Dr. Burton oversaw and managed the UC Davis Transitions of Care program, a service that encompasses Med Rec on admission, discharge, and discharge education for 6 hospital units, and include high risk patients across the hospital for 7 years. From 2018 to 2020, Dr. Burton served as Interim Assistant Chief of Pharmacy over Central Inpatient Operations, prior to starting a new role as the Associate Chief of Population Health and serving as UC Davis’s Population Health Lead for Pharmacy. She views her participation on collaborative projects as a step towards tighter collaboration between medical centers, pharmacists, and the improvement in patient care.

    Selected Publications

    Oct 2015 SB493: Making the Case for Other Providers. JL Burton, TK Pon. California Pharmacist. Winter 2015. Pp 17-20.

    May 2015 Analysis of the Impact of a Pharmacist Within a Patient Centered Medical Home. M Devens, S Roberts, Pharm.D., BCPS, S Marin, Pharm.D., JL Burton. Presented a Western States Conference 2015.

    Jan/Feb 2015 Implementing a Successful Transitions Program while Avoiding Common Pitfalls. JL Burton. CJHP. Vol 27. No 1. Pp 7-14.

    Aug 2013 JL Burton. BCPS for Dummies. CJHP July/Aug Issue, Volume 25, Number 4. pp128-130

    Feb 2012 Borgsdorf L, Burton JL, Chen S, Jeong E, Jew R, Kawahara, BI, Khatibi P, Kootsikas M, Stebbins M, Valenzuela L. Medication Therapy Management Resource Guide. CJHP 2012;24(2):42-52.

    April 2008 Contributor Joint Commission’s Anticoagulation Resource Handbook. Ladan Cockshut, writer. Janet Pimentel, Senior Editor,

    Feb 2006 WH Dager, JM Branch, JL Burton, JL Bandy, RH White “A Look at UCDMC Anticoagulation Services” Drug Perspectives, UCD Feb 2006

    Oct 1999 M Ferrill, JL Burton “Treatment of Anxiety, Depression and Bipolar Disorders” California Pharmacists Association Journal Oct 1999

    Selected Presentations

    Expanding Pharmacy Services using Residents, PCPC, CSHP. May 2021

    Defining Pharmacy’s Role in Population Health, UC Davis Quality Forum. Mar 2021.

    Clearing the Way for Strategy: Back to Basics, Vizient Pharmacy meeting. Oct 2020.

    Transition of Care Improvements at Two Academic Medical Centers. Vizient meeting, Orlando, Florida. Dec 2017.

    The Next Step: Using your clinical knowledge to overcome barriers and justify expansion of amcare services. A practical approach. CSHP Seminar, Anaheim. Oct 2016.

    Bridging the Gap: An Amcare Perspective – 2014 AMCP Western Regional Conference. June 2014.

    Daily Dose: Utilizing Preceptees as an Indispensable Part of Daily Pharmacy Practice at ASHP Midyear. Dec 2013.

    Monica Donnelley
    Email: mdonnelley@ucdavis.edu

    Current Title(s):

    • Senior Pharmacist, UCD Health, Infectious Diseases
    • PGY2 Infectious Diseases Residency Program Director
    • Assistant Clinical Professor:
      • Touro University, College of Pharmacy
      • UC Davis, School of Medicine
      • UC San Francisco, School of Pharmacy

    Education:

    PharmD., Touro University, Mare Island, 2010

    Post-graduate Training:

    PGY1 Pharmacy Practice Residency, UC Davis Medical Center, 2010-2011

    PGY2 Infectious Diseases Residency, UC Davis Medical Center, 2011-2012

    Research Interests

    New agents: antimicrobials and antifungals, antimicrobial dosing in critically ill, improving antimicrobial stewardship services, Outpatient Parenteral Antimicrobial Therapy (OPAT), and reducing C. difficile infections.

    Practice Philosophy

    I am an antimicrobial advisor. My goal is to create customized therapy plans for each patient based on a multitude of factors. Understand that each patient is different from the neonate to someone’s great-grandmother, the gymnast from the linebacker. The world of ID is fascinating and not only is the patient and the drug involved critical to consider in therapy decisions, but we must also consider the “bug” where did it come from, is it resistant, and can we reach it with our therapy.

    Rotations Precepted

    Infectious Diseases Consult (PGY1 and PGY2)

    Antimicrobial Stewardship (PGY1 and PGY2)

    Infectious Diseases Pediatric Consult (PGY2)

    Additional PGY2 ID rotations precepted, please see PGY2 in Infectious Diseases Link

    Professional Biography

    Dr. Monica Donnelley is board certified in infectious diseases and pharmacotherapy. She is also certified as an American Association of HIV Pharmacist. She is a Senior Pharmacist at UC Davis Health. Dr. Donnelley began her pharmacy career at UC Davis Health in 2010 after graduating from pharmacy school. At Touro University College of Pharmacy, she was the recipient of the Mylan Institute Pharmacy Excellency Award and won the California Society of Health System Pharmacist Clinical Skills Competition. She went on to complete a PGY1 Pharmacy Practice Residency and PGY2 Infectious Diseases Residency at UC Davis Health.

    Following completion of her ID PGY2 she accepted a position with UC Davis Health, focusing on infectious diseases and medication safety. Concurrently she also began teaching at Touro University (TU), College of Pharmacy in the Clinical Sciences track and obtained a volunteer faculty position as an assistant professor with the University of San Francisco, College of Pharmacy and the University of California, Davis School of Medicine. In 2013 she was awarded Professor of the Year in Clinical Sciences at TU.

    After practicing for five years at UC Davis Health, Dr. Donnelley was promoted to Senior Pharmacist and in 2016 she assumed directorship of the long standing PGY2 infectious diseases residency program upon the retirement of her PGY2 residency director Cinda Christensen. For the 2016–2017 year, she was awarded Residency Preceptor of the Year and in 2017–2018 she received the Research Preceptor of the Year award. Monica loves to work with learners. She contributes to the care of patients through actively rounding with infectious diseases, research, publications, committee work, and guideline development.

    Jeremiah J. Duby
    Email: jjduby@ucdavis.edu

    Current Title(s):

    • Senior Clinical Pharmacist
    • Assistant Clinical Professor, Touro University College of Pharmacy
    • Assistant Clinical Professor, UC San Francisco School of Pharmacy
    • Assistant Clinical Professor, UC Davis School of Medicine

    At UC Davis Medical Center since: 2007

    Program Director since: 2010

    Education:

    • PharmD, Washington State University, 2003
    • PGY-1 Acute Care Residency, University of Arizona, 2004
    • PGY-2 Critical Care Pharmacy Residency, University of Arizona, 2005

    Professional Biography

    Dr. Jeremiah Duby is the Senior Critical Care Pharmacist and Specialty Critical Care Residency Program Director for UC Davis Medical Center. He serves as Assistant Clinical Professor for Touro University (TU) College of Pharmacy, UCSF School of Pharmacy, and UC Davis School of Medicine.  His principle practice is in clinical patient care with Trauma Surgery, Burn Surgery, Medical ICU, and Parenteral Nutrition services.  These activities serve as inspiration for his roles in policy and protocol development and research.  Additionally, he provides didactic lectures for TU and UC San Francisco students on acute care topics that include clinical pharmacokinetics, fluid/electrolyte abnormalities, acute pain, sepsis/septic shock, acid-base disorders, skin-soft tissue infections, pneumonia, and clinical toxicology.  Current research interests range from alcohol withdrawal syndrome to diabetic ketoacidosis to acute arrhythmias.

    Dr. Duby graduated from Washington State University (2003) and then a completed pharmacy practice residency (PGY-1, 2004, William L. Fritz, MS, FASHP) and critical care residency (PGY-2, 2005, Brian L. Erstad, Pharm.D., FCCM) with an emphasis in infectious diseases and nutrition at the University of Arizona Medical Center (UAMC).  He first served as an infectious diseases pharmacist for Kaiser Permanente (2005 – 2007), helping pilot and establish a successful antimicrobial stewardship service with Stephen M. Parodi, M.D., which later became as model of patient care for the region.

    Selected Publications

    Nagle E, Dager WE, Duby JJ, Roberts A, Murthy M, Kenny L, Pretzlaff R. Bivalirudin in pediatric patients maintained on extracorporeal life support. Pediatric Critical Care Medicine. (pending press).

    Nagle E, Murthy M, Medina M, Floyd K, Love, D, Duby JJ. Nursing clinical discretion and decisions in the provision of pharmacotherapy in the intensive care unit. [abstract/poster]. 42nd Critical Care Congress. San Juan, Puerto Rico: Display and Professor Walk Rounds. January 20, 2012.

    Bajorek S, Duby JJ, Heintz S, Heintz H, Cocanour CS. Risk factors, prevalence, course, and complications of atrial fibrillation in critically ill trauma patients. 42nd Critical Care Congress. San Juan, Puerto Rico: Display and Professor Walk Rounds. January 20, 2013.

    Murthy M, Nagle E, Parker P, Duby JJ. Dose response effect of rescue intravenous dextrose for hypoglycemia in critically ill patients. 42nd Critical Care Congress. San Juan, Puerto Rico: Display and Oral Presentation. January 20, 2013.

    Berry A, Cocanour CS, Duby JJ. Management of Alcohol Withdrawal Syndrome (AWS) that Complicates the Course of Critically Ill Patients. [abstract/poster]. 41st Critical Care Congress. Houston, TX: Display and Professor Walk Rounds. February 7, 2012.

    Murthy M, Nagle E, Duby JJ, Roach D, Parker P. Dose Response to Rescue Intravenous Dextrose Administration following Hypoglycemic Events with an Insulin Infusion Protocol in Critically Ill Burn Patients. [abstract/poster]. 41st Critical Care Congress. Houston, TX: Display and Professor Walk Rounds. February 7, 2012.

    Nagle E, Pretzlaff R, Duby JJ, Roberts JA,Murthy M, Dager WE. A Case Series Describing the Use of Bivalirudin in Pediatric Patients Maintained on Extracorporeal Life Support. [abstract/poster]. 41st Critical Care Congress. Houston, TX. February 4, 2012.

    Von Muenster SJ, Cocanour CS, Duby JJ. Prevalence and Course of Atrial Fibrillation (AF) in Critically Ill Trauma Patients. [abstract/poster]. Annual Meeting. Western Surgical Association. Tucson, AZ: Podium Presentation, November 13, 2011.

    Matzke GR, Duby JJ. Vancomycin. In: Murphy JE. Clinical Pharmacokinetics. 5th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2011.

    Duby JJ, Heintz BH. Clostridium difficile Associated Diarrhea. In: Katz MD, Matthias KR, Chisholm-Burns MA. Pharmacotherapy Principles and Practice Study Guide: A Case-Based Care Plan Approach. New York, NY: McGraw-Hill; 2010: 327 - 329.

    Duby JJ. Ketamine: Pharmacology, Controversy, and Role. Clinical Pharmacy and Pharmacology Section Newsletter. Society of Critical Care Medicine. July 2010; 10(2).

    Kopp B, Mrsan M, Erstad BL, Duby JJ. Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. American Journal of Health-System Pharmacy. 2007; 64: 2483 – 2487.

    Duby JJ, Erstad BL, Abarca J, Camamo JM, Huckleberry Y, Bramblett SN. Impact of delayed initiation of erythropoietin in critically ill patients. Blood Disorders. 2007; 7:1.

    Duby JJ, Rollins CJ. Survey of nurse administration of phenytoin through enteral feeding tubes concomitantly with enteral nutrition. Poster: ASHP 2007 Summer Meeting and Exhibition. San Francisco, CA. June 25, 2007.

    Patanwala AE, Duby JJ, Waters D, Erstad BL. Opioid Conversion in Acute Care. Annals of Pharmacotherapy. 2007; 41(2): 255 – 266.

    Brent Hall
    Email: brahall@ucdavis.edu

    Current Title(s):

    • Pharmacist Specialist, Pediatrics
    • Associate Clinical Professor, UCSF School of Pharmacy

    At UC Davis Medical Center since: 2014

    Program Director since: 2015

    Education:

    • PGY 1 Northwestern Memorial Hospital, Chicago, IL, July 1999-June 2000
    • PharmD, Purdue University School of Pharmacy, 1999
    • B.S. Biology/Physiology, Purdue University School of Science, 1998

    Professional Biography

    Brent Hall is currently a Pharmacist Specialist in Pediatrics at the UC Davis Medical Center. After completion of his residency, Brent accepted a position at University Medical Center in Tucson, Arizona. This institution served as the teaching hospital for the University of Arizona Schools of Pharmacy, Medicine, Nursing and Public Health. Brent first served as a staff pharmacist in pediatrics before advancing to the position of Clinical Coordinator for Pediatric Pharmacy.  Over the 14 years that he spent in Arizona he was able to grow his service from 1 FTE to 4 FTEs with an expanding precepting program for University of Arizona pharmacy students as well as helping to lay the groundwork for the development of a PGY 2 Pediatric Pharmacy Residency Program. Brent was also very active in the Schools of Pharmacy, Medicine and Nursing providing didactic lectures, precepting and course coordination. In 2014, Brent moved his practice to Sacramento, California to help with the establishment of the PGY 2 Pediatric Pharmacy Residency Program and expansion of clinical services. Brent is actively involved with programs at UC Davis Children’s Hospital which include Pharmacy Residency Advisory Committee, Pharamcy Research Oversight Committee, UC Wide Preceptor Development Committee, Acute Care Practice Council Representative, Peer Responder, Co-Chair of the Department of Pharmacy Committee on Education, Pediatric Heart Center Group for protocol development, Pediatric Medication Error Committee and PICU Committee Representative. Nationally he is actively involved in ACCP, PPAG and has worked on the A-F Bundle Project with SCCM as well as Opioid Stewardship programs with Delphi. Brent currently serves as the ACCP Pediatric PRN Education Chair and Core Competency Chair for PPA. Brent’s areas of interest include critical care medicine, cardiology, sedation/delirium management, pain control and precepting.

    Selected Publications

    • Haftmann, R; Pineda, E; Hall, B; et al. “Comparison of Time Within Therapeutic Range Using Anti-Factor Xa versus Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin in Children.” Journal of Pediatric Pharmacology and Therapeutics, in print
    • Lammers, C; Schwinghammer, A; Hall, B; Kriss, R, et al. "Comparison of Oral Loading Dose to Intravenous Acetaminophen in Children For Analgesia After Tonsillectomy and Adenoidectomy: A Randomized Clinical Trial" Anesth Analg. Dec 1, 2021; 133(6): 1568-76.
    • Valdivia HR, Hall BA, Fitzgerald A, et al. ICU Liberation in the pediatric intensive care unit: Bridging the A-F bundle to the bedside of the critically ill child. In: Posa P, Sigh, J, Stollings J, eds. ICU Liberation, Second Edition. Mt Prospect, IL: Society of Critical Care Medicine.
    • Schwinghammer, A, Wilson, M, Hall, B. “QTc prolongation in hospitalized pediatric patients receiving methadone”. Pediatric Crit Care Med, 2018, Aug; 19(8): e403-8.
    • Grant, M; Schneider, J; Asaro, L, et al. “Dexmedetomidine Use in Critically Ill Children with Acute Respiratory Failure”. Pediatric Crit Care Med, 2016 Dec; 17(12):1131-41.
    • Beall, V; Hall, B; Mulholland, J, et al. “Neonatal Extravasation: An Overview and Algorithm for Evidence-Based Treatment” Newborn and Infant Nursing Reviews Journal, Vol 13, Number 4, December 2013, pp189-95.

    Current Research Projects

    • "Comparison of 30 mg/kg of Metronidazole vs standard 8 mg/kg q8 dosing for colorectal surgery prophyalxis - A Non-Inferiority Trial." Whalen, R; Hall, B; Saadi, P. In protocol development
    • “Retrospective Cohort Study Assessing Safety of Non Steroidal Agents in Children 1 to 6 months of age.” Patel, A; McCann, T; Haftman, R; Schwinghammer, A; Stein J; Hall, B. IRB approved, in Progress.
    • “Randomized, Placebo Controlled, Trial to Evaluate the Use of Gabapentin in Pediatric Cardiothoracic Surgery Patients to Reduce Opioid Requirements Post Operatively” Hall, B; Raff, G; Stein, J. – IRB approved, enrolling

    Chad Hatfield
    Email: cjhatfield@ucdavis.edu

    Current Title(s):

    • Chief Pharmacy Officer
    • PGY-1 and PGY-2 HSPAL Residency Director
    • Associate Dean, UCSF School of Pharmacy

    At UC Davis Medical Center since: 2018

    Program Director since: 2021

    Education:

    • Doctor of Pharmacy, Oregon Health and Science University/Oregon State University, 2005
    • PGY1 Pharmacy Practice Residency, Scripps Mercy Medical Center, 2007
    • Masters of Health Administration, Simmons College of Management, 2013

    Professional Biography

    Dr. Chad Hatfield is board certified in pharmacotherapy.  He is the Chief Pharmacy Officer for UC Davis Health, which has ~500 staff supporting 13 operational pharmacies, the acute and ambulatory clinical services and 39 pharmacy residents.  Dr. Hatfield began his pharmacy career at Kaiser Permanente San Diego Medical Center after graduating from pharmacy school where he found a passion for hospital practice.  Dr. Hatfield, then went back to complete a PGY1 residency with Scripps Mercy Medical Center in San Diego, California.  Upon completion, he accepted a Clinical Specialist position in Emergency Medicine at Grady Memorial Hospital in Atlanta, Georgia.  Dr. Hatfield took his first formal leadership role at Emory University Hospital where he oversaw inpatient operations and PGY1 Acute Care Residency Program where he spent 4 years.  Dr. Hatfield then spent 6 years at the University of North Carolina, Chapel Hill.  During Dr. Hatfield’s tenure at UNC, he oversaw a variety of clinical and operations.  Since August 2018, Dr. Hatfield has held the position of Chief Pharmacy Officer at the UC Davis and Assistant Dean, UCSF School of Pharmacy. His role further expanded in 2021 as the residency director for the PGY1/PGY2 HSPAL program.

    Featured Publications and Presentations

    Maximizing Margins. Strategies to Optimizing Medication Pricing, Utilization and Revenue. Webinar Dec 2021

    Hood D, Cutler T, St. Angelo E, Trask A, Hatfield C, Green A. Rapid Establishment of COIVD-19 Vaccination Clinics. Pharmacy Purchasing & Products. July 2021

    Lyons K, Griggs D, Lebovic R, Roth ME, South D, Hatfield C. The University of North Carolina Medical Center Pharmacy Resident Leadership Certificate Program. Am J Health Syst Pharm. March 2017;74(6):430-436.

    O’Neil DP, Miller A, Cronin D, Hatfield CJ. A Comparison of Automated Dispensing Cabinet Optimization Methods. Am J Health Syst Pharm. 2016; Jul 1; 73(13): 975-80.

    Mann JE, Dipper A, Rowe E, Hatfield C. Lean Six Sigma in the Pharmacy Department. Pharmacy Times, September 2014.

    O’Neil DP, Sautman HL, Hatfield CJ. Missing Doses: A System at Fault. Hosp Pharm. 2014; Jul: 49(7): 591-3.

    Polly DM, Paciullo CA, Hatfield CJ. Management of Hypertensive Emergency and Urgency. Advanced Emergency Nursing Journal. 2011; 33(2): 127-136.

    Kronmann L, Hatfield C, and Kronmann K. Statin Therapy, Not Just Used to Lower Cholesterol? Crit Care Nurs Q. 2007. 30(2): 154-160.

    Andrea Iannucci
    Email: aaiannucci@ucdavis.edu

    Current Title(s):

    • Assistant Chief, Oncology and Investigational Drug Services
    • Oncology Pharmacy Specialist, UC Davis Medical Center Pharmacy Services
    • Health Sciences Clinical Professor, UC San Francisco School of Pharmacy and UC Davis School of Medicine

    At UC Davis Medical Center since: 2002

    Program Director since: 2004

    Education:

    • PharmD, UC San Francisco School of Pharmacy
    • PGY1 Pharmacy Residency, UC San Francisco
    • PGY2 Oncology Residency, MD Anderson Cancer Center

    Professional Biography

    Dr. Andrea Iannucci has practiced in oncology pharmacy for 25 years. In the past, she has also served as a full-time faculty member at the University of Colorado School of Pharmacy and as the Director of Clinical Services for the Rocky Mountain Cancer Centers.  Andrea joined the UC Davis Pharmacy team in 2002 as a Senior Oncology Pharmacist.  She started the PGY2 Oncology Residency Program in 2004 and has graduated nearly 20 oncology pharmacists from the program.  Andrea has served as an IRB member with the UC Davis Medical Center IRB. She currently serves as a member of the UC Davis Cancer Center Scientific Review Committee. Andrea is the co-chair of the Oncology Sub-Committee of the UC Davis Pharmacy and Therapeutics Committee and she oversees the operations of oncology pharmacy and investigational services at UC Davis.   Andrea has also been involved in the Board of Pharmaceutical Specialties (BPS) Oncology Specialty Council and most recently served on the BPS Board of Directors, where she has served as the BPS chair. 

    Selected Publications

    Iannucci A, Reed Jeanne, Bell T.  “Chapter 21: Cancer and Chemotherapy” in Pharmacology Essentials for Technicians, 2011; Paradigm Publishing, Inc. (St. Paul, MN).

    Rao, KV, Iannucci AA, Jabbour E.  Current and Future Clinical Strategies in the Management of Chronic Myeloid Leukemia.  Pharmacotherapy 2010;30(9 Pt 2):77S–101S.

    Superfin D, Iannucci AA, Davies A. Commentary: Oncologic Drugs in Organ dysfunction: A Summary. The Oncologist, 2007;12;1070-1083.

    Iannucci A and Chan, A.  “Management and Treatment of Hematologic Toxicities” in Unit 3, Supportive Care in Mosby’s Oncology Drug Reference, 2007; Mosby Elsevier (St. Louis, MO).

    Stull DM, Iannucci A, Bertin R.  Board-Certified Oncology Pharmacists: Partners in the Multidisciplinary Care of Cancer Patients. Community Oncology, 2006;3(5):284-286.

    Balmer CM, Valley AW, Iannucci A.  Cancer Treatment and Chemotherapy in Pharmacotherapy: A Pathophysiologic Approach, 6th Edition.  DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors, 2005, McGraw-Hill Companies, Inc.

    Chan A, Iannucci A, Dager WE. Systemic Anticoagulant Prophylaxis for Central Catheter-associated Venous Thrombosis in Cancer Patients.  Annals of Pharmacotherapy 2007, 41:635-641.

    Gibbs P, Iannucci A, Allen J, O'Driscoll M, McDowell K, Williams P, Rosse P, Murphy J, Gonzalez R.  A Phase II Study of Biochemotherapy for the Treatment of Metastatic Malignant Melanoma.  Melanoma Research, 2000; 10: 171-179.

    Jennifer Murphy
    Email: jemurphy@ucdavis.edu

    Current Title(s):

    • Senior Clinical Pharmacist
    • Assistant Clinical Professor of Pharmacy, UCSF
    • Adjunct Clinical Professor, California Northstate University
    • PGY2 Investigational Drug Services Program Director

    At UC Davis Medical Center since: 2013

    Program Director since: 2022

    Education:

    • Doctor of Pharmacy, UCSF, 2011
    • PGY1 Acute Care Pharmacy Residency, UCSD, 2012
    • PGY2 Oncology Residency, UC Davis Health, 2013

    Professional Biography

    Dr. Jennifer Murphy graduated with her Doctor of Pharmacy from the UC San Francisco School of Pharmacy where she won the ASHP National Clinical Skills Competition and SNPhA National Clinical Skills Competition. After graduation, she completed an Acute Care PGY1 Residency at UC San Diego Health System and a PGY2 Residency in Oncology at UC Davis Health.

    As a board-certified oncology pharmacist, her primary area of practice is the UCDH Cancer Center Investigational Drug Service. In this role, she is actively involved in oncology clinical trial protocol development and quality improvement projects as well as various institutional committees. Additionally, she supports the Inpatient Hematology/Oncology, Bone Marrow Transplant and Gynecologic Oncology services. Dr. Murphy developed the Pharmacy Residency Mentorship Committee in 2014 and co-chairs the Committee. Dr. Murphy has served as an adjunct faculty and guest lecturer at California Northstate University, College of Pharmacy and currently holds a volunteer faculty position as an assistant professor at UCSF School of Pharmacy.

    Selected Publications

    Chang Munoz M, Murphy JA, Wolff JE, Jonas BA. Prolonged Response of a Patient with Relapsed Acute Myeloid Leukemia to a Novel Oral Bromodomain Extraterminal Inhibitor (BETi). Case Rep Hematol. 2020 Dec 15; 2020:8830123.

    Bermingham R, Murphy J, Noto N. (2009, May 30). Closing Poison Center Will Cost State Money [Letter to the Editor]. San Diego Union-Tribune B7.

    Baker H, Murphy J, Song, J. Myopathy Associated with Daptomycin Use. Infectious Disease Alert. Sept 2006.

    Targeted Therapies January 2022 Continuing Education for Advanced Practitioners Horizon CME: Oncology 101

    Selected Presentations

    Safe Handling and Best Practices for Storage of Medications March 2016 ASHP Accredited Webinar-based Pharmacy Technician Continuing Education ASHP PharmTech CE Portal

    “Investigating” the Role of the Pharmacy Technician February 2015 in Investigational Drug Services ASHP Accredited Webinar-based Pharmacy Technician Continuing Education ASHP PharmTech CE Portal

    “Investigating” the Role of the Pharmacy Technician February 2015 in Investigational Drug Services ASHP Accredited Webinar-based Pharmacy Technician Continuing Education ASHP PharmTech CE Portal

    Clinical Trials 101: Investigational Drug Services July 2014, 2015, 2016, 2017 University of California, Davis Health Presented at the Hematology/Oncology Fellows Conference

    A. Josh Roberts
    Email: ajroberts@ucdavis.edu

    Current Title(s):

    • Pharmacist Specialist - Cardiology, UC Davis Medical Center
    • Associate Clinical Professor of Pharmacy (WOS), UC San Francisco School of Pharmacy

    At UC Davis Medical Center since: 2007

    Program Director since: 2021

    Education:

    • University of Pacific, Thomas J Long School of Pharmacy (2005)
    • University of Tennessee, Knoxville, Medical Center (2006)

    Professional Biography

    Dr. Roberts hold two board certifications – cardiology pharmacist and pharmacotherapy specialist with added qualifications in cardiology. Additionally, he is an Associate of the American College of Cardiology. He is a Pharmacist Specialist with greater than 14 years of experience at UC Davis Medical Center. As a preceptor and teacher for over 12 years, Dr. Roberts has received six “Apples for Preceptors” awards and a “Preceptor of the Year – Long Teaching Award.” His areas of practice are acute care cardiology, cardiac surgery, complex anticoagulation management, and thrombosis and hemostasis management. Dr. Roberts is a member of the American Society of Health-Systems Pharmacist, American College of Cardiology, International Society of Thrombosis and Haemostasis, Anticoagulation Forum, and American College of Clinical Pharmacy. He currently serves as a peer reviewer for Annals of Pharmacotherapy and Journal of Pharmacy Technology. He has also served as an expert reviewer for American College of Clinical Pharmacy, Pharmacotherapy Self-Assessment Program. Dr. Roberts has authored or coauthored over a dozen journal articles and book chapters, and given numerous invited local, national, and international podium and poster presentations.

    Selected Publications

    Dager W, Li D, Roberts J. Prevention and Treatment of Venous Thromboembolism. In: Brian Erstad, ed. Critical Care Pharmacotherapy. Bethesda, MD: American Society of Health-System Pharmacists. (in press)

    Roberts J, Dager W. Unfractionated Heparin, Low Molecular Weight Heparin, and Fondaparinux. In: Murphy J, ed. Clinical Pharmacokinetics, 7th edition. Bethesda, MD: American Society of Health-System Pharmacists.2021

    Kulig C, Roberts AJ, Rowe AS, Kim H, Dager WE. “INR Response to Low-Dose Vitamin K in Warfarin Patients. Ann Pharmacother. 2021 Feb 5:1060028021993239

    Gosselin RC, Roberts AJ, Dager WE. "The Joint Commission National Patient Safety Goals (NPSG) Directing Anticoagulation Safety in the United States." Annals of Blood [Online], 4 (2019): n. pag. Web. 24 Jun. 2020

    Dager WE, Roberts AJ, Nishijima DK. Effect of Low and Moderate Dose FEIBA to Reverse Major Bleeding in Patients on Direct Oral Anticoagulants. Thromb Res. 2019;173:71-76

    Walker EA, Roberts AJ, Louie EL, Dager WE. Bivalirudin Dosing Requirements in Adult Patients on Extracorporeal Life Support With or Without Continuous Renal Replacement Therapy. ASAIO J. 2019;65:134-138

    Dager W, Roberts J. Chapter 5: Parenteral Direct Thrombin Inhibitors. In: Dager W, Gulseth M, Nutescu E, eds. Anticoagulation Therapy: A Point-of-Care Guide, 2nd edition. Bethesda, MD: American Society of Health-System Pharmacists.2018

    van Cott EM, Roberts AJ, Dager WE. Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors. Semin Thromb Hemost. 2017;43:270-276

    Roberts J, Dager W. Unfractionated Heparin, Low Molecular Weight Heparin, and Fondaparinux. In: Murphy J, ed. Clinical Pharmacokinetics, 6th edition. Bethesda, MD: American Society of Health-System Pharmacists. 2017

    Chen LD, Roberts AJ, Dager WE. Safety and efficacy of starting warfarin after two consecutive platelet count rises in heparin-induced thrombocytopenia. Thromb Res. 2016; 144:229-33.

    Dager W, Roberts J. Chapter 23: Prevention and Treatment of Venous Thromboembolism. In: Brian Erstad, ed. Critical Care Pharmacotherapy. Bethesda, MD: American Society of Health-System Pharmacists. 2016

    Pon TK, Dager WE, Roberts AJ, White RH. Subcutaneous Enoxaparin for Therapeutic Anticoagulation in Hemodialysis Patients. Thromb Res. 2014;133(6):1023-8

    Roberts A, Sutter M, Dager W. Reversal of Novel Anticoagulants: Role of Clotting Factors and Complex Concentrates. Curr Emerg Hosp Med Rep. 2013;1:200–207

    Dager WE, Gosselin RC, Roberts AJ. Reversing dabigatran with FEIBA in a patient with a transseptal perforation during cardiac ablation. Crit Care Med. 2013;41(5):e42-6

    Nagle EL, Dager WE, Duby JJ, Roberts AJ, Kenny LE, Murthy MS, Pretzlaff RK. Bivalirudin in pediatric patients maintained on extracorporeal life support. Pediatr Crit Care Med. 2013;14:e182-8

    Gosselin R, Dager W, Roberts A, et al. Effect of telavancin (vibativ) on routine coagulation test results. Am J Clin Pathol. 2011;136(6):848-54

    Dager W, Roberts J. Unfractionated Heparin, Low Molecular Weight Heparin, and Fondaparinux. In: Murphy J, ed. Clinical Pharmacokinetics, 5th edition. Bethesda, MD: American Society of Health-System Pharmacists.2011

    Ashley Trask
    Email: atrask@ucdavis.edu

    Current Title(s):

    • Associate Chief Pharmacy Officer, Quality and Safety

    At UC Davis Health since: 2002

    Program Director since: 2016

    Education:

    • PGY-1 Pharmacy Residency, University of California, Davis Medical Center, 2002
    • PharmD, University of Florida, 2002

    Professional Biography

    Dr. Ashley Trask is the Medication Policy & Safety Pharmacist Supervisor, overseeing pharmacy teams who support the Pharmacy & Therapeutics committee, medication safety and medication security efforts at University of California Davis Health.  She received her Doctor of Pharmacy from the University of Florida, College of Pharmacy in 2002, and completed her Pharmacy Practice Residency at UC Davis Medical Center in 2003. Dr. Trask took an interest in pain management and began her pharmacy career in 2003 at UC Davis as a Pain Management Pharmacist, providing consultations for inpatients. After many years of serving patients at the bedside, Dr. Trask transitioned into a more administrative role, where she began engaging in quality improvement activities associated with medication-related events and assisting the health system in complying with new state laws directed at medication safety. Dr. Trask has a passion for equipping clinicians with the skills to improve the safe use of medications in their practice settings. Dr. Trask is a member of several interdisciplinary task forces and committees focused on improving the quality and safety of healthcare for patients at UC Davis Health.  She was promoted to her current role as a pharmacy supervisor in 2015 and serves as the residency director for the Post Graduate Year 2 Pharmacy Practice Resident in Medication Use Safety, as well as the primary preceptor for pharmacy students and pharmacy practice residents on the Medication Safety and Hospital Operations rotations.  Dr. Trask currently resides in Sacramento with her husband and three sons.

    Featured Presentations

    Drug Shortages and Surplus Risk- Addressing Drug Shortages with a Patient Safety Perspective, CSHP Seminar 18, October 5, 2018
    RADEO Project Interdisciplinary Group Meeting, UC Davis ANCC Magnet Site Visit, August 2018
    Reducing Opioid Adverse Drug Events, Vizient Webinar, Performance Improvement Collaboratives Series 2017—Program 1, October 25, 2017
    A Pilot Program at UC Davis Medical Center to Reduce Adverse Drug Events Related to Opioids, Greater Sacramento Care Coordination Learning and Action Network Conference, October 9, 2017

    Selected Publications

    Assessing the Effectiveness of a Clinical Decision Support Tool on Recognition and Documentation of Suspected Heparin-Induced Thrombocytopenia (HIT). [poster] UC Davis Quality Symposium; April 2015.
    Repurposed Data to Measure Physician Quality of Care– Can Prescribing Errors be Detected from Decision Support Systems Data? [abstract] EDM Forum Stakeholder Symposium; June 2013.

    Becks Wittenberg
    Email: rwittenberg@ucdavis.edu

    Current Title(s):

    • Senior Pharmacist, UC Davis Health, Infectious Diseases Specialty Pharmacy
    • PGY2 Ambulatory Care Residency Program Director

    At UC Davis Medical Center since: 2014
    Program Director since: 2021

    Education:

    • Doctor of Pharmacy, University of California, San Diego, 2014
    • PGY1 Ambulatory Care/HIV Pharmacy Residency, UC Davis Medical Center, 2015
    • PGY2 Ambulatory Care, UC Davis Health, 2016

    Professional Biography

    Dr. Rebecca Wittenberg is a Specialty Pharmacist at UC Davis Medical Center. Dr. Wittenberg began her pharmacy career in 2014 after graduating from the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Science. She then went on to complete both a PGY1 and PGY2 residency at UC Davis Medical Center from 2014 to 2016.

    Publications

    Nguyen MV H, Davis MR, Wittenberg RR, McHardy I, Baddley JW, Young BY, Odermatt A, Thompson GR III. Posaconazole Serum Drug Levels Associated with Pseudohyperaldosteronism. CID. 2019.

    Thompson GR 3rd, Chang D, Wittenberg RR, McHardy J, Semrad A, In Vivo 11β-Hydroxysteroid Dehydrogenase Inhibition in Posaconazole-Induced Hypertension and Hypokalemia. Antimicrob Agents Chemother. 2017.

    Presentations

    Nguyen MV H, Davis MR, Wittenberg RR, McHardy I, Baddley JW, Young BY, Odermatt A, Thompson GR III. Posaconazole Serum Drug Levels Associated with Hypertension and Hypokalemia: The Syndrome of Pseudohyperaldosteronism. In: 9th Trends in Medical Mycology (TIMM). Nice, France: October 13th, 2019. Poster #088.

    Nguyen MV H, Davis MR, Wittenberg RR, McHardy I, Baddley JW, Young BY, Odermatt A, Thompson GR III. Posaconazole Serum Drug Levels Associated with Pseudohyperaldosteronism. In: IDWeek Conference 2019. Washington DC, USA: October 3, 2019. Poster #732.

    Thompson GR III, Chang D, Wittenberg RR, McHardy I, Semrad A. Posaconazole Induced Hypertension and Hypokalemia: Mechanistic Evaluation. In: IDWeek Conference 2017. San Diego, CA.

    Cagonot, V., Wittenberg, R., Hamai, E., The effect of combination therapy with a biologic compared to biologic monotherapy on clinical remission for inflammatory bowel disease. Western States Conference 2017. San Diego, CA.

    Wittenberg, R. and Hamai, E., Impact of a Pharmacist in the IBD Clinic. Western States Conference 2016. San Diego, CA.

    Wittenberg, R., Vongspanich, V., Poole, P., Effect of efavirenz vs. rilpivirine on vitamin D levels among treatment-experienced HIV-1 infected adults. Western States Conference 2015. San Diego, CA.